The Department of Radiation Oncology and our faculty are involved with numerous active clinical trials as sponsors and collaborators. Our current active studies are listed below. If you have any questions about the particular study, please contact the study coordinator.
Feinberg Clinical Trials
Scientists at the medical school are conducting hundreds of clinical trials daily. Learn more about all our work via the Feinberg Office of Research Clinical Trials page. Search for trials by disease or condition.
Clinical Research Office
Find more about the clinical research done within the Robert H. Lurie Comprehensive Cancer Center through the Clinical Research Office.
|Adam Brakman||Eric Donnelly, MD||A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer|
|Adam Brakman||Bharat Mittal, MD||Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer|
|Adam Brakman||Samir Sejpal, MD||A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors|
|Adam Brakman||Eric Donnelly, MD||A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (Time-C)|
|Rachel Bers||Eric Donnelly, MD||A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone (ANZGOG 0902/GOG-0274/RTOG 1174)|
|Adam Brakman||Eric Donnelly, MD||Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy|
|Adam Brakman||John Hayes, MD||Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed By Sorafenib In Hepatocellular Carcinoma|
|Adam Brakman||John Hayes, MD||A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma|
|Adam Brakman||John Hayes, MD||A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma|
|Adam Brakman||MaryAnne Marymont, MD||Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation And Consolidative Extra-Cranial Irradiation For Extensive Disease Small Cell Lung Cancer (ED-SCLC)|
|Adam Brakman||John Kalapurakal, MD||Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis|
|Adam Brakman||Eric Donnelly, MD||A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy|
|Rachel Bers||John Hayes, MD||A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer|
|Rachel Bers||Eric Donnelly, MD||A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy|